The main line of investment in the medical sector is still focused on three points: innovative drugs, consumption upgrading and medical insurance policy.
The R&D and profit of innovative drugs is a virtuous circle process, which can support leading enterprises to become stronger and bigger. Compared with top foreign pharmaceutical companies, pharmaceutical companies in the A-share market still have a lot of room for growth. China's population base and aging trend are also the guarantee to support the future trend of medical stocks.
The concept of consumption upgrading in medical industry is relatively broad, such as medical beauty, children's health care, elderly health care, auxiliary medication, family medical care, corrective surgery and so on. Many fields are still in the emerging stage. With the improvement of residents' attention to health, the demand in this area will be more and more vigorous. The stock of medical consumer enterprises is a potential emerging stock, which can easily lead to the situation of rising volume and price.
Finally, we should pay attention to the impact of medical insurance policy on the pharmaceutical sector. As a key link of people's livelihood, medical insurance is mainly to reduce costs from the perspective of national adjustment policies. For some pharmaceutical companies, the reduction of unit price of goods is tantamount to the decline of revenue, but the increase of market share helps to strengthen competition barriers. So from a fundamental point of view, whether it is good or bad depends on the future trend.
Although the stock market expects the policy to advance rapidly, we should still pay attention to the influence of the policy on market sentiment in the short term. Therefore, in general, the current medical sector investment should pay attention to safety first. The short-term suggestion is to pay close attention to policy news and subdivide the leading stocks in the medical sector.